{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:50:43Z","timestamp":1791489043409,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"DOI":"10.1038\/s41371-026-01200-2","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:48:10Z","timestamp":1787226490000},"page":"817-823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular events with esaxerenone versus spironolactone in hypertension"],"prefix":"10.1038","volume":"40","author":[{"given":"Takashin","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2553-6170","authenticated-orcid":false,"given":"Hidehiro","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhito","family":"Fujiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Azegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1838-7998","authenticated-orcid":false,"given":"Takashi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"1200_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.14240","volume":"75","author":"FD Fuchs","year":"2020","unstructured":"Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75:285\u2013292.","journal-title":"Hypertension"},{"key":"1200_CR2","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u20131481.","journal-title":"Hypertens Res"},{"key":"1200_CR3","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334\u20131357.","journal-title":"Hypertension"},{"key":"1200_CR4","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018.","journal-title":"Eur Heart J"},{"key":"1200_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coph.2016.02.005","volume":"27","author":"J Yang","year":"2016","unstructured":"Yang J, Young MJ. Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences. Curr Opin Pharmacol. 2016;27:78\u201385.","journal-title":"Curr Opin Pharmacol"},{"key":"1200_CR6","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","volume":"43","author":"AK Pandey","year":"2022","unstructured":"Pandey AK, Bhatt DL, Cosentino F, Marx N, Rotstein O, Pitt B, et al. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Eur Heart J. 2022;43:2931\u20132945.","journal-title":"Eur Heart J"},{"key":"1200_CR7","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1080\/00498254.2016.1263766","volume":"47","author":"M Yamada","year":"2017","unstructured":"Yamada M, Takei M, Suzuki E, Takakusa H, Kotsuma M, Washio T, et al. Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys. Xenobiotica. 2017;47:1090\u20131103.","journal-title":"Xenobiotica"},{"key":"1200_CR8","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u20132263.","journal-title":"N Engl J Med"},{"key":"1200_CR9","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219\u20132229.","journal-title":"N Engl J Med"},{"key":"1200_CR10","doi-asserted-by":"crossref","unstructured":"Chen YH, Fang YW, Chen MT, Liou HH, Tsai MH. Nonsteroidal Mineralocorticoid Receptor Antagonists and Cardiovascular Events in Type 2 Diabetes: A Retrospective Study. European Heart Journal \u2013 Cardiovascular Pharmacotherapy. 2025;11:610\u20139.","DOI":"10.1093\/ehjcvp\/pvaf048"},{"key":"1200_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","volume":"16","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, et al. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2022;16:293\u2013302.","journal-title":"Clin Kidney J"},{"key":"1200_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). Hypertension. 2020;75:51\u201358.","journal-title":"Hypertension"},{"key":"1200_CR13","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41440-024-01762-z","volume":"47","author":"K Kario","year":"2024","unstructured":"Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, et al. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study. Hypertens Res. 2024;47:2435\u20132446.","journal-title":"Hypertens Res"},{"key":"1200_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.37737\/ace.25006","volume":"7","author":"H Yasunaga","year":"2025","unstructured":"Yasunaga H. DeSC database. Ann Clin Epidemiol. 2025;7:46\u201349.","journal-title":"Ann Clin Epidemiol"},{"key":"1200_CR15","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","volume":"158","author":"WA Ray","year":"2003","unstructured":"Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915\u2013920.","journal-title":"Am J Epidemiol"},{"key":"1200_CR16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u2013992.","journal-title":"Am J Kidney Dis"},{"key":"1200_CR17","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","volume":"367","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:l5657.","journal-title":"BMJ"},{"key":"1200_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.37737\/ace.25012","volume":"7","author":"Y Hashimoto","year":"2025","unstructured":"Hashimoto Y, Yasunaga H. Propensity score analysis revisited. Ann Clin Epidemiol. 2025;7:99\u2013104.","journal-title":"Ann Clin Epidemiol"},{"key":"1200_CR19","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","volume":"179","author":"U Kintscher","year":"2022","unstructured":"Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022;179:3220\u20133234.","journal-title":"Br J Pharmacol"},{"key":"1200_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, B\u00e4rfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1200_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E, Chudek R, Blumrich A, Ban Z, et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone\u2019s Antifibrotic Activity. Hypertension. 2018;71:599\u2013608.","journal-title":"Hypertension"},{"key":"1200_CR22","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41440-019-0211-0","volume":"42","author":"AS Bhuiyan","year":"2019","unstructured":"Bhuiyan AS, Rafiq K, Kobara H, Masaki T, Nakano D, Nishiyama A. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice. Hypertens Res. 2019;42:892\u2013902.","journal-title":"Hypertens Res"},{"key":"1200_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.896947","volume":"13","author":"X Jiang","year":"2022","unstructured":"Jiang X, Zhang Z, Li C, Zhang S, Su Q, Yang S, et al. Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes: a systematic review incorporating an indirect comparisons meta-analysis. Front Pharmacol. 2022;13:896947.","journal-title":"Front Pharmacol"},{"key":"1200_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/hr.2009.86","volume":"32","author":"M Nagase","year":"2009","unstructured":"Nagase M, Fujita T. Mineralocorticoid receptor activation in obesity hypertension. Hypertens Res. 2009;32:649\u2013657.","journal-title":"Hypertens Res"},{"key":"1200_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1681\/ASN.2020071041","volume":"32","author":"N Ayuzawa","year":"2021","unstructured":"Ayuzawa N, Fujita T. The mineralocorticoid receptor in salt-sensitive hypertension and renal injury. J Am Soc Nephrol. 2021;32:279\u2013289.","journal-title":"J Am Soc Nephrol"},{"key":"1200_CR26","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s12325-024-02780-6","volume":"41","author":"HA Uchida","year":"2024","unstructured":"Uchida HA, Nakajima H, Hashimoto M, Nakamura A, Nunoue T, Murakami K, et al. Efficacy and safety of esaxerenone in hypertensive patients with left ventricular hypertrophy (ESES-LVH) study: A multicenter, open-label, prospective, interventional study. Adv Ther. 2024;41:1284\u20131303.","journal-title":"Adv Ther"},{"key":"1200_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102637","volume":"13","author":"JL Harrington","year":"2025","unstructured":"Harrington JL, Canonico ME, El Rafei A, Solomon SD, Teerlink JR, Vaduganathan M, et al. Nonsteroidal and steroidal mineralocorticoid antagonists: rationale, evidence, and unanswered questions. JACC Heart Fail. 2025;13:102637.","journal-title":"JACC Heart Fail."},{"key":"1200_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/cvr\/cvad165","volume":"120","author":"Z Tian","year":"2024","unstructured":"Tian Z, Vollmer Barbosa C, Lang H, Bauersachs J, Melk A, Schmidt BMW. Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis. Cardiovasc Res. 2024;120:108\u2013119.","journal-title":"Cardiovasc Res"},{"key":"1200_CR29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3109\/10641960903407017","volume":"31","author":"M Yutaka","year":"2009","unstructured":"Yutaka M, Mifune M, Kubota E, Itoh H, Saito I. Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker. Clin Exp Hypertens. 2009;31:648\u2013656.","journal-title":"Clin Exp Hypertens"},{"key":"1200_CR30","doi-asserted-by":"publisher","first-page":"e0500","DOI":"10.1097\/MD.0000000000010500","volume":"97","author":"Y Liu","year":"2018","unstructured":"Liu Y, Dai S, Liu L, Liao H, Xiao C. Spironolactone is superior to hydrochlorothiazide for blood pressure control and arterial stiffness improvement: A prospective study. Medicine (Baltimore). 2018;97:e0500.","journal-title":"Medicine (Baltimore)"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01200-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01200-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01200-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:02:53Z","timestamp":1791486173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01200-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1038\/s41371-026-01200-2","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.K. and K.F. received research funding and scholarship support from\u00a0Medtronic Japan Co., LTD, Boston Scientific Japan Co., LTD, BIOTRONIK JAPAN INC, SIMPLEX QUANTUM Inc, and UT-Heart Inc. H.K. holds shares in PrevMed Co., Ltd. and Japan Preventive Medicine Development Institute Co., Ltd. K.N. has received honoraria from Novartis, Novo Nordisk, Mochida, Otsuka, Daiichi Sankyo; Research grant from Fuji Yakuhin, Novartis Pharma, Bayer Yakuhin, Mochida Pharmaceutical; Scholarship from Boehringer Ingelheim Japan, Abbott Medical Japan.\u00a0T.N.\u00a0is an employee of Nippon Boehringer Ingelheim Co., Ltd.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}